Cross Keys Capital Advises Bucks-Mont Eye Associates, P.C., in its Partnership with Vision Innovation Partners
January 09, 2024 08:00 ET
|
Cross Keys Capital, LLC.
Fort Lauderdale, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Cross Keys Capital Healthcare (Cross Keys), a leading independent investment banking firm providing M&A advisory services to physician group...
Curative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of Directors
January 08, 2024 09:45 ET
|
Curative Biotechnology, Inc.
Appointment of Independent Director Nominee to become effective upon approval by and listing of common stock on a National Exchange Boca Raton, FL, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Curative...
Kriya Provides Update on Pipeline Progress Ahead of Company Presentation at 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024 09:00 ET
|
Kriya Therapeutics, Inc.
– Kriya anticipates up to 5 programs to enter clinic by the end of 2025 – – Current pipeline of gene therapies for common diseases spans three major therapeutics areas: ophthalmology, metabolic...
USAN Approves Generic Name “Ruxoprubart” for NM8074, an Antibody Therapy focused on Complement-Mediated Diseases
January 08, 2024 08:30 ET
|
NovelMed Therapeutics Inc
The USAN Council has officially adopted "Ruxoprubart (Ruk”soe proo' bart)" as the generic name for NM8074, marking a significant milestone in the drug development process.Ruxoprubart is an...
Regenerative Medicine Market Set to Hit USD 194.9 Billion by 2032, Driven by Robust CAGR of 19.4%
January 08, 2024 07:35 ET
|
Market.Us
New York, Jan. 08, 2024 (GLOBE NEWSWIRE) -- According to the market.us, the anticipated value of the Global Regenerative Medicine Market is projected to reach approximately USD 194.9 billion by the...
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease
January 08, 2024 07:00 ET
|
OKYO Pharma LTD
Statistically significant drug effects were observed in FDA-recognized efficacy endpoints as early as the 15-day first visit after dosingStatistically significant improvement was observed in both a...
Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies
January 05, 2024 16:00 ET
|
Molecular Partners
Collaboration leverages lead-based (212Pb) alpha emitter expertise and supply of Orano Med with Molecular Partners’ leadership in DARPins for tumor-targeted delivery of radioactive...
Kriya Announces Gene Therapy Program for Thyroid Eye Disease
January 05, 2024 09:00 ET
|
Kriya Therapeutics, Inc.
– KRIYA-586 is designed to be a one-time treatment delivered by focal peribulbar injection, that encodes an antibody blocking the Insulin-Like Growth Factor 1 Receptor (IGF-1R), a clinically validated...
Bionic Eye Market Size Set to Soar USD 199.97 Million by 2032
January 04, 2024 10:08 ET
|
Precedence Research
Ottawa, Jan. 04, 2024 (GLOBE NEWSWIRE) -- The global bionic eye market size accounted for USD 92.89 million in 2023 and is projected to surpass around USD 132.44 million by 2029. The industry is...
Ashvattha Therapeutics Announces the Appointment of Mehdi Paborji as Senior Vice President of Technical Operations
January 04, 2024 08:30 ET
|
Ashvattha Therapeutics
REDWOOD CITY, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue...